WallStSmart

The Ensign Group Inc (ENSG)vsFresenius Medical Care Corporation (FMS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 288% more annual revenue ($19.63B vs $5.06B). ENSG leads profitability with a 6.8% profit margin vs 5.0%. FMS appears more attractively valued with a PEG of 0.77. FMS earns a higher WallStSmart Score of 62/100 (C+).

ENSG

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.34

FMS

Buy

62

out of 100

Grade: C+

Growth: 7.3Profit: 5.0Value: 10.0Quality: 7.0
Piotroski: 6/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSGFair Value (-0.1%)

Margin of Safety

-0.1%

Fair Value

$211.64

Current Price

$200.08

$11.56 premium

UndervaluedFair: $211.64Overvalued
FMSUndervalued (+73.4%)

Margin of Safety

+73.4%

Fair Value

$90.32

Current Price

$21.64

$68.68 discount

UndervaluedFair: $90.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

FMS4 strengths · Avg: 9.5/10
P/E RatioValuation
11.6x10/10

Attractively priced relative to earnings

Price/BookValuation
0.4x10/10

Reasonable price relative to book value

EPS GrowthGrowth
420.0%10/10

Earnings expanding 420.0% YoY

PEG RatioValuation
0.778/10

Growing faster than its price suggests

Areas to Watch

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.804/10

Expensive relative to growth rate

P/E RatioValuation
34.3x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

FMS4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
7.9%3/10

ROE of 7.9% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

Revenue GrowthGrowth
-30.0%2/10

Revenue declined 30.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, EPS Growth. PEG of 0.77 suggests the stock is reasonably priced for its growth.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Bear Case : FMS

The primary concerns for FMS are Altman Z-Score, Return on Equity, Profit Margin. Thin 5.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

ENSG profiles as a growth stock while FMS is a value play — different risk/reward profiles.

FMS carries more volatility with a beta of 0.94 — expect wider price swings.

ENSG is growing revenue faster at 20.2% — sustainability is the question.

FMS generates stronger free cash flow (564M), providing more financial flexibility.

Bottom Line

FMS scores higher overall (62/100 vs 57/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Want to dig deeper into these stocks?